Disclosed is a pharmaceutical composition comprising, as active ingredients, a corticosteroid and a B2 kinin receptor antagonist, together with pharmaceutically acceptable carriers and excipients, wherein: a.) the corticosteroid, either natural or synthetic, is selected from Cortisone, Hydrocortisone, Beclomethasone, Betamethasone, Budesonide, Dexamethasone, Flumethasone, Flunisolide, Fluocortone, Fluticasone, Methylprednisolone, Methylprednisone, Paramethasone, Prednisolone, Triamcinolone, optionally in the form of an ester with acetic, benzoic, caproic, succinic, phosphoric, propionic or valeric acid, or in the form of acetonide b.) the B2 kinin receptor antagonist is selected from: - H-D-Arg-Arg-Pro-Hyp-Gly-Igl-Ser-D-F5F-Igl-Arg-OH - H-Arg-Arg-Pro-Hyp-Gly-Igl-Ser-D-Igl-Oic-Arg-OH - H-D-Arg-Arg-Pro-Hyp-Gly-Thi-Ser-D-Tic-Oic-Arg-OH (Icatibant) - 4-[2-[([[3-(3-Bromo-2-methyl-imidazo[ 1.2-a]pyridine-8-yl oxymethyl)-2,4-dichloro-phenyl]-methyl-carbamoyl]-methy1)carbamoyl]-vinyl]-N,N-dimethyl-benzamide - 3-(6-Acetylamino-pyridin-3-yl)-N-([[2,4-dichloro-3-(2-methylquinolin-8-yl oxymethyl)-phenyl]-methyl-carbamoyl]-methyl)-acrylamide -1-[2,4-Dichloro-3-(2,4-dimethy l-quinolin-8-yl oxymethy 1)-benzene sulfonyl]-pyrrolidine-2-carboxylic acid [3-(4-carbamidoyl-benzoylamino )-propyl]-amide (Anatibant) - Bradizide - 4-( 4-[1-[2,4-Dichloro-3 -(2,4-dimethy l-quinolin-8-y I oxymethy 1)-benzenesulfonyl]-pyrrolidine-2-carbonyl]-piperazine-1-carbonyl)-benzamidine - 2-[5-(4-Cyano-benzoyl)-1-methyl-1H-pyrrol-2-yl]-N-[2,4-dichloro-3-(2-methly-quinoline-8-yl oxymethyl)-phenyl]-N-methyl-acetamide -or a compound of general formula (I), wherein the substituents are as described within the specification. Further disclosed is the use of a corticosteroid and a B2 kinin receptor antagonist for the preparation of a medicament for the prevention or therapy of articular and respiratory tract inflammation, lesion and degeneration,
